EliseAI Raises $350M at $4B Valuation as ARR Tops $200M
EliseAI raises $350 million at a $4 billion valuation after passing $200 million in ARR, with Apollo expanding its housing and healthcare automation.
Summary
EliseAI announced a $350 million funding round on September 29, 2026, co-led by Andreessen Horowitz and Bessemer Ventures. The deal values the AI startup at $4 billion, twice its Series E valuation in August 2025. Founded in 2017, EliseAI automates administrative and operational work for housing and healthcare companies. Its software serves 1 in 6 apartments nationwide, and annual recurring revenue passed $200 million in summer 2026.
EliseAI launched Apollo in September 2026, an AI teammate embedded in its existing platform that supports leasing, maintenance and renewals across property teams. For specialty physician groups, the company automates patient paperwork spanning inbound calls, referrals, scheduling, insurance verification, chart preparation and follow-up. Co-founder and CEO Minna Song said EliseAI targets housing and healthcare because they are among American households’ largest expenses. The company did not disclose how it will use the new capital.
Positives
- The $350 million round gives EliseAI substantial capital to expand its housing and healthcare automation business.
- The $4 billion valuation is twice EliseAI’s Series E valuation from August 2025.
- Annual recurring revenue surpassed $200 million during summer 2026.
- EliseAI software now serves 1 in 6 apartments nationwide.
- Apollo integrates leasing, maintenance and renewal tasks within the platform already used by property teams.
- Healthcare workflows cover the patient journey from inbound calls through insurance verification, chart preparation and follow-up.
Risks & concerns
- EliseAI did not disclose how it will deploy the $350 million round.
- No adoption or performance figures were provided for Apollo after its September 2026 launch.
- The company provided no healthcare customer count comparable with its 1 in 6 apartment reach.